The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Alaunos Therapeutics Inc. (TCRT) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.0294, or 3.72%, to $0.82. The Alaunos Therapeutics Inc. has recorded 4,744 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023.
Alaunos Therapeutics Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $0.79 and fluctuated between $0.8151 as its day high and $0.7400 as its day low. The current market capitalization of Alaunos Therapeutics Inc. is $182.21M. A total of 1.34 million shares were traded on the day, compared to an average of 1.70M shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, TCRT has seen 2 BUY and 0 SELL insider trades, representing the acquisition of 2,000,000 and the disposition of 0 shares. Over the last 12 months, there were 11 BUYs and 1 SELLs from insiders. Insiders purchased 2,440,000 shares during that period but sold 18,750.
In the most recent transaction, Postma Robert W bought 750,000 shares of TCRT for 0.65 per share on Nov 29. After the transaction, the Director now owns 5,000,000 company shares. In a previous transaction on Nov 29, Vieser Jaime bought 1,250,000 shares at 0.65 per share. TCRT shares that Director owns now total 1,250,000.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for TCRT in the last 3 months, the mean price target is $3.75 with high estimates of $7.50 and low estimates of $1.25. In terms of 52-week highs and lows, TCRT has a high of $4.01 and a low of $0.41.
As of this writing, TCRT has an earnings estimate of -$0.08 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.05 per share and a lower estimate of -$0.17. The company reported an EPS of -$0.05 in the last quarter, which was 28.60% higher than expectations of -$0.07.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TCRT is Overweight with a score of 4.00. A total of 4 analysts rated the stock as Buy while 0 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.